Leerink Partnrs Has Pessimistic View of ALNY FY2026 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Wednesday, April 2nd. Leerink Partnrs analyst M. Foroohar now expects that the biopharmaceutical company will post earnings per share of $0.07 for the year, down from their prior forecast of $0.12. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03).

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $280.00 to $328.00 in a report on Monday, March 24th. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a “buy” rating and a $353.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Sanford C. Bernstein reduced their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $316.25.

Alnylam Pharmaceuticals Trading Down 10.1 %

Shares of NASDAQ ALNY opened at $235.74 on Friday. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a 50-day moving average of $259.03 and a two-hundred day moving average of $260.33. The company has a market cap of $30.67 billion, a PE ratio of -108.64 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,017,271.63. This represents a 11.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 over the last ninety days. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $28,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $33,000. Colonial Trust Co SC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $35,000. Finally, OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.